Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

Tumour budding is an emerging prognostic biomarker in colorectal cancer (CRC) and other
solid cancers. Tumour buds are usually defined as isolated single cancer cells or clusters of …

The human genome contains 19 putatively functional aldehyde dehydrogenase (ALDH)
genes, which encode enzymes critical for detoxification of endogenous and exogenous …

Colorectal cancer (CRC) is the third cause of cancer death worldwide. Although, in some
cases, treatment can increase patient survival and reduce cancer recurrence, in many …

One of the current stumbling blocks in our fight against cancer is the development of
acquired resistance to therapy, which is attributable to approximately 90% of cancer-related …

Recent evidence suggests that enhanced aldehyde dehydrogenase (ALDH) activity is a
hallmark of cancer stem cells (CSC) measurable by the aldefluor assay. ALDH1A1, one of …

Identifying and sorting highly tumorigenic and metastatic tumor cells from a heterogeneous
cell population is a daunting challenge. Here, we show that microfluidic devices can be used …

Normal stem cells and cancer stem cells (CSCs) share similar properties, in that both have
the capacity to self-renew and differentiate into multiple cell types. In both the normal stem …

Resistance to current chemotherapeutic or radiation-based cancer treatment strategies is a
serious concern. Cancer stem cells (CSCs) are typically able to evade treatment and …

Abstract Background Mesenchymal stromal cells (MSCs) are multipotent progenitor cells
used in several cell therapies. MSCs are characterized by the expression of CD73, CD90 …